WILMINGTON, Del--Zoladex (goserelin acetate implant), Zeneca Pharmaceuticals'
gonadotropin-releasing-hormone (GnRH) agonist, has received approval
for use in the treatment of advanced breast cancer in premenopausal
and perimenopausal women.
The agent was introduced in the United States for the treatment
of advanced prostate cancer in 1989 and for the treatment of endometriosis
Zoladex, given by injection once a month, acts on the pituitary
gland to cause decreased production of estrogen by the ovaries.
This lowers serum estrogen levels to concentrations typical of
postmenopausal women, reducing estrogen stimulation of breast
The new indication is based on results of clinical trials involving
more than 800 women in North America and Europe, showing response
rates and survival benefits comparable to those achieved by oophorectomy,
the company said.